Vizient Celebrates Over 1,000 Facility Participants in the Clinical Data Base

IRVING, Texas–(BUSINESS WIRE)–Vizient, Inc. today announces the Vizient Clinical Data Base® recently welcomed its 1,000th hospital participant, a milestone that marks its place as the definitive analytics platform for hospital performance and financial improvement. Vizient is the largest member-driven healthcare performance improvement company in the U.S. and serves more than half the nation’s healthcare providers. … [Read more…]

Global Precision Diagnostics Market Analysis/Forecasts 2022-2028: Artificial Intelligence and Machine Learning Gaining Traction & Growing Advancement In Digital Solutions – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Precision Diagnostics Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Type, Application, and End User” report has been added to ResearchAndMarkets.com’s offering. The global precision diagnostics market is expected to grow from US$ 79,776.88 million in 2022. to US$ 1,68,405.71 million by 2028. Factors such as the increasing demand for … [Read more…]

Community Oncology Services Global Market to Reach $74.87 Billion by 2026 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Community Oncology Services Global Market Report 2022, By Type, By Cancer Type, By Therapy Type” report has been added to ResearchAndMarkets.com’s offering. The global community oncology services market is expected to grow from $70.06 billion in 2021 to $70.56 billion in 2022 at a compound annual growth rate (CAGR) of 0.7%. The slow … [Read more…]

Genexine selected for Late-Breaking Oral Presentation of Phase 2 Study of GX-188E in Combination with KEYTRUDA® (pembrolizumab) in Cervical Cancer at European Society for Medical Oncology (ESMO) Congress 2022

SEOUL, South Korea–(BUSINESS WIRE)–Genexine (KOSDAQ: 095700), a publicly traded, clinical-stage Korean biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of unmet medical needs, announced today that late-breaking results from the Phase 2 clinical trial study of its therapeutic DNA vaccine GX-188E in combination with MSD’s (Merck & Co., Inc., … [Read more…]

AncestryDNA® Expands to 54 New Markets Globally

LEHI, Utah–(BUSINESS WIRE)–Ancestry®, the global leader in family history and consumer genomics, today announced it has expanded AncestryDNA® to 54 new markets across North America, South America, Europe, Asia, and Africa. Now available to consumers in 89 countries and territories on five continents, this expansion more than doubles the number of markets where people can … [Read more…]

Oncoinvent Initiates Radspherin® Phase 2A Trial

First patient has been treated in the RAD-18-002 phase 2A clinical study OSLO, Norway–(BUSINESS WIRE)–Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of cancers, today announced that the first colorectal cancer patient in the RAD-18-002 phase 2A clinical trial has been treated with its drug candidate, Radspherin®. The study is … [Read more…]

Galderma Delivers Strong H1 2022 Results and Continued Innovation Across Its Leading Dermatology Portfolio

ZUG, Switzerland–(BUSINESS WIRE)–Galderma: Continued strong commercial and financial performance in a resilient market Galderma delivered continued strong growth across product categories, with net sales up 15% year-on-year on a constant currency basis at 1,914 M USD Particularly strong performance of Injectable Aesthetics and Dermo-cosmetics product categories with growth of 32% and 31% on a constant … [Read more…]

Biocytogen Expands Partnership with Merck

BEIJING & DARMSTADT, Germany–(BUSINESS WIRE)–#License–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) entered into a global licensing agreement with Merck for the use of Biocytogen’s RenMice™ platform. Under the terms of the agreement, Merck will have full access to Biocytogen’s RenMice™ platform to discover and develop fully human antibody therapeutics for an unlimited number of drug targets. … [Read more…]

Ligand Announces that Janssen has Received Approval from European Commission for TECVAYLI® (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

First European Commission approval of a bispecific antibody discovered using OmniAb OmniAb, Inc. is eligible to receive a $10 million milestone upon first commercial sale in Europe EMERYVILLE, Calif.–(BUSINESS WIRE)–Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that the Janssen Biotech, Inc. (Janssen) received conditional marketing authorization (CMA) from the European Commission for TECVAYLI® (teclistamab) as monotherapy … [Read more…]

Phibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year Results, Provides Financial Guidance

TEANECK, N.J.–(BUSINESS WIRE)–Phibro Animal Health Corporation (Nasdaq:PAHC) (“Phibro” or the “Company”) today announced financial results for its fourth quarter and fiscal year ended June 30, 2022, and provided financial guidance for the year ending June 30, 2023. Highlights for the three months ended June 30, 2022 (compared to the three months ended June 30, 2021) … [Read more…]